Advertisement

Der Schmerz

, Volume 24, Issue 6, pp 587–595 | Cite as

Modafinil zur Behandlung der Tumorfatigue

Eine Interventionsstudie
  • S. WirzEmail author
  • J. Nadstawek
  • K.U. Kühn
  • S. Vater
  • U. Junker
  • H.C. Wartenberg
Originalien

Zusammenfassung

Ziel

Die Autoren führten eine Open-label-Untersuchung durch, um den Effekt von Modafinil zur Behandlung der Tumorfatigue bei Patienten mit einer Tumorerkrankung, antiproliferativen Therapie und Opioidgabe zu evaluieren.

Methoden

Nach Genehmigung durch die örtliche Ethikkommission und Patienteneinwilligung wurden Tumorpatienten mit Fatigue, definiert als anhaltende Schwäche sowie eingeschränkte Fähigkeit zu körperlicher und geistiger Arbeit, in die Studie eingeschlossen. Die Patienten erhielten „open-label“ 100 mg/Tag Modafinil. Vor (t1), 7 Tage (t2) und 28 Tage (t3) nach Beginn der Medikation wurden Fatigue Severity Score (FSS), Epworth Sleeping Scale (ESS) und eine Visuelle Analogskala (Müdigkeit; VAS; 0–10) durchgeführt. Zusätzlich wurden der d2-Aufmerksamkeitstest nach Brickenkamp, die Hamilton Depression Scale (HAMD), der Eastern-Cooperative-Oncology-Group-Score (ECOG), Nebenwirkungen und Therapiezufriedenheit dokumentiert.

Ergebnisse

Von 37 eingeschlossenen Patienten lagen bei Studienende komplette Daten von 29 Patienten vor. Modafinil verbesserte signifikant die Werte von FSS (t1 44,6±12,2, t2 39±12,4, t3 35,3±13,8; p=0,015) und VAS (Müdigkeit; VAS t1 6±3,1, t2 4,5±2,8, t3 3,7±2,8; p=0,005) und nicht signifikant Parameter des d2-Tests und ESS. Die Werte des ECOG und der Patientenzufriedenheit wiesen keine Veränderung auf. Schwerwiegende Nebenwirkungen wurden nicht beobachtet

Schlussfolgerungen

Bei Patienten mit einer Tumorschmerztherapie steigerte Modafinil Wachheit und kognitive Fähigkeiten. Trotz der Vorläufigkeit der Ergebnisse weist dies möglicherweise auf eine Verbesserung der Lebensqualität durch Modafinil bei dieser Patientengruppe hin. Dennoch müssen der Off-label-Status einer solchen Therapie und die Notwendigkeit einer sorgfältigen Fatiguediagnostik beachtet werden. Randomisierte kontrollierte Studien stehen zur Verbesserung der Evidenzlage aus.

Schlüsselwörter

Tumorfatigue Modafinil Karzinom Opioid Schmerz 

Modafinil for the treatment of cancer-related fatigue

An intervention study

Abstract

Aim

The authors conducted an open-label investigation examining the effects of modafinil in reducing fatigue in patients with cancer, undergoing cancer treatment, and receiving opioid therapy.

Methods

After approval by the local Ethics Committee and informed consent cancer patients who reported fatigue – defined as persistent tiredness interfering with usual functioning – were enrolled in the study. Once daily, patients received 100 mg open-label modafinil. The Fatigue Severity Scale (FSS), Epworth Sleepiness Scale (ESS), and a visual analogue scale (VAS, 0–10) were performed at baseline (t1), day 7 (t2), and day 28 (t3). Further assessment comprised the d2 Test of Attention (d2), the Hamilton Depression Scale (HAMD), the Eastern Cooperative Oncology Group-Score (ECOG), side effects, and patients’ satisfaction with modafinil treatment.

Results

Of the 37 patients who were enrolled, 29 completed all assessments in the study. Modafinil had a significant effect on the FSS (t1 44.6+/−12.2, t2 39+/−12.4, t3 35.3+/−13.8 (p=0.015), on the VAS (t1 6+/−3.1), t2 4.5+/−2.8, t3 3.7+/−2.8 (p=0.005), and an insignificant effect on d2 parameters of neurophysiological functioning and ESS. No differences were seen for ECOG and patients’ satisfaction. No severe adverse effects were detected.

Conclusion

Modafinil improved alertness and cognitive skills in patients receiving cancer pain treatment by enhancing vigilance and cognitive performance. Although confirmation of this preliminary result is needed, these findings suggest that modafinil may improve quality of life in this patient population. However, in Germany the use of modafinil for fatigue is off-label and careful assessment of fatigue is needed prior to treatment. Randomized controlled trials are needed to confirm this evidence.

Keywords

Fatigue Modafinil Cancer Opioids Pain 

Notes

Danksagung

Die Autoren bedanken sich bei den Ambulanzschwestern der Schmerzambulanz der Klinik und Poliklinik für Anästhesiologie und Operative Intensivmedizin der Universitätskliniken Bonn, Marta Dederichs, Annette Dahlhaus, Christiane Statz und Kathleen Wolf, die diese Untersuchung unterstützt haben. Dank an Sonja Vater für die sorgfältige Datenerhebung. Dank an Sonja Vater, Uwe Junker und Amelie Wirz für die Datenanalyse. Dank an Ronel Kranz für die Sichtung des englischen Abstracts.

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: Herr Dr. Stefan Wirz war in den vergangenen Jahren als Referent für die Firmen Cephalon, Lilly, Mundipharma und Grünenthal tätig.

Literatur

  1. 1.
    Blackhall L, Petroni G, Shu J et al (2009) A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue. J Palliat Med 12(5):433–439CrossRefPubMedGoogle Scholar
  2. 2.
    Brickenkamp R (2002) Allgemeine Leistungstests, 9. Aufl. Hogrefe, GöttingenGoogle Scholar
  3. 3.
    Brown JN, Howard CA, Kemp DW (2010) Modafinil for the treatment of multiple sclerosis-related fatigue. Ann Pharmacother 44(6):1098–1103CrossRefPubMedGoogle Scholar
  4. 4.
    Bruera E, Driver L, Barnes EA et al (2003) Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 1;21(23):4439–4443Google Scholar
  5. 5.
    Bruera E, Valero V, Driver L et al (2006) Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 1;24(13):2073–2078Google Scholar
  6. 6.
    Carroll JK, Kohli S, Mustian KM et al (2007) Pharmacologic treatment of cancer-related fatigue. Oncologist 12:43–51CrossRefPubMedGoogle Scholar
  7. 7.
    Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACTAn) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34:13–19PubMedGoogle Scholar
  8. 8.
    Cella D, Peterman A, Passik S et al (1998) Progress toward guidelines for the management of fatigue. Oncology (Williston Park) 12(11A):369–377Google Scholar
  9. 9.
    Cella D, Davis K, Breitbart W et al (2001) Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 19:3385–3391PubMedGoogle Scholar
  10. 10.
    Cooper MR, Bird HM, Steinberg M (2009) Efficacy and safety of modafinil in the treatment of cancer-related fatigue. Ann Pharmacother 43(4):721–725CrossRefPubMedGoogle Scholar
  11. 11.
    Curt GA, Breitbart W, Cella D (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5(5):353–360CrossRefPubMedGoogle Scholar
  12. 12.
    Fleishman S, Lower E, Zeldis J et al (2005) A phase II, randomized, placebo-controlled trial of the safety and efficacy of dexmethylphenidate (d-MPH) as a treatment for fatigue and „chemobrain“ in adult cancer patients. Breast Cancer Res Treat 94:S214Google Scholar
  13. 13.
    Gallopin T, Luppi PH, Rambert FA et al (2004) Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study. Sleep 27(1):19–25PubMedGoogle Scholar
  14. 14.
    Given CW, Given B, Azzouz F et al (2001) Predictors of pain and fatigue in the year following diagnosis among elderly cancer patients. J Pain Symptom Manage 21:456–466CrossRefPubMedGoogle Scholar
  15. 15.
    Glaus A (1998) Fatigue in patients with cancer – analysis and assessment. Recent Results Cancer Res 145:54–76Google Scholar
  16. 16.
    Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62CrossRefPubMedGoogle Scholar
  17. 17.
    Hann DM, Jacobsen PB, Azzarello LM et al (1998) Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res 7(4):301–310CrossRefPubMedGoogle Scholar
  18. 18.
    Jacobsen PB, Donovan KA, Weitzner MA (2003) Distinguishing fatigue and depression in patients with cancer. Semin Clin Neuropsychiatry 8:229–240PubMedGoogle Scholar
  19. 19.
    Jean-Pierre P, Figueroa-Moseley CD, Kohli S et al (2007) Assessment of cancer-related fatigue: implications for clinical diagnosis and treatment. Oncologist 12(Suppl 1):11–21CrossRefPubMedGoogle Scholar
  20. 20.
    Jean-Pierre P, Morrow GR, Roscoe JA et al (2010) A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer 15;116(14):3513–3520Google Scholar
  21. 21.
    Johns MW (1991) A new method of measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 14:540–545PubMedGoogle Scholar
  22. 22.
    Kim SH, Son BH, Hwang SY et al (2008) Fatigue and depression in disease-free breast cancer survivors: prevalence, correlates, and association with quality of life. J Pain Symptom Manage 35(6):644–655CrossRefPubMedGoogle Scholar
  23. 23.
    Kohli S, Fisher SG, Tra Y (2009) The effect of modafinil on cognitive function in breast cancer survivors. Cancer 15;115(12):2605–2616Google Scholar
  24. 24.
    Krupp LB, LaRocca NG, Muir-Nash J et al (1989) The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123PubMedGoogle Scholar
  25. 25.
    Lawrence DP, Kupelnick B, Miller K (2004) Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr (32):40–50Google Scholar
  26. 26.
    Minton O, Richardson A, Sharpe M et al (2008) A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 100:1155–1166CrossRefPubMedGoogle Scholar
  27. 27.
    Minton O, Richardson A, Sharpe M et al (2010) Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev 7;7:CD006704Google Scholar
  28. 28.
    Moraska AR, Sood A, Dakhil SR et al (2010) Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 Trial. J Clin Oncol 10;28(23):3673–3679Google Scholar
  29. 29.
    Morrow GR, Shelke AR, Roscoe JA (2005) Management of cancer-related fatigue. Cancer Invest 23(3):229–239CrossRefPubMedGoogle Scholar
  30. 30.
    National Comprehensive Cancer Network (2006) Cancer-related fatigue panel 2006 guidelines. http://www.nccn.or1982 g/professionals/physician_gls/f_guidelines.aspGoogle Scholar
  31. 31.
    Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655CrossRefPubMedGoogle Scholar
  32. 32.
    Radbruch L, Sabatowski R, Elsner F et al (2003) Validation of the German version of the brief fatigue inventory. J Pain Symptom Manage 25(5):449–458CrossRefPubMedGoogle Scholar
  33. 33.
    Radbruch L, Strasser F, Elsner F et al (2008) Research Steering Committee of the European Association for Palliative Care (EAPC). Fatigue in palliative care patients – an EAPC approach. Palliat Med 22(1):13–32CrossRefPubMedGoogle Scholar
  34. 34.
    Ryan JL, Carroll JK, Ryan EP et al (2007) Mechanisms of cancer-related fatigue. Oncologist 12(Suppl 1):22–34CrossRefPubMedGoogle Scholar
  35. 35.
    Sarhill N, Walsh D, Nelson KA (2001) Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care 18(3):187–192CrossRefPubMedGoogle Scholar
  36. 36.
    Sharpe M, Strong V, Allen K (2004) Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. Br J Cancer 26;90(2):314–320Google Scholar
  37. 37.
    Sinnott C (2002) Problems recruiting cancer patients to a comparative clinical trial of drug treatments for neuropathic pain in palliative care. J Pain Symptom Manage 23(4):270–272CrossRefPubMedGoogle Scholar
  38. 38.
    Spathis A, Dhillan R, Booden D (2009) Modafinil for the treatment of fatigue in lung cancer: a pilot study. Palliat Med 23(4):325–331CrossRefPubMedGoogle Scholar
  39. 39.
    Stone P, Hardy J, Broadley K et al (1999) Fatigue in advanced cancer: a prospective controlled cross-sectional study. Br J Cancer 79:1479–1486CrossRefPubMedGoogle Scholar
  40. 40.
    Stone P, Richards M, A’Hern R et al (2000) A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 11:561–567CrossRefPubMedGoogle Scholar
  41. 41.
    Vaishnavi S, Gadde K, Alamy S (2006) Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment. J Clin Psychopharmacol 26:373–378CrossRefPubMedGoogle Scholar
  42. 42.
    Vogelzang NJ, Breitbart W, Cella D (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34(3 Suppl 2):4–12PubMedGoogle Scholar
  43. 43.
    Webster L, Andrews M, Stoddard G (2003) Modafinil treatment of opioid-induced sedation. Pain Med 4(2):135–140CrossRefPubMedGoogle Scholar
  44. 44.
    Zifko UA, Rupp M, Schwarz S (2002) Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 249(8):983–987CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • S. Wirz
    • 1
    Email author
  • J. Nadstawek
    • 2
  • K.U. Kühn
    • 3
  • S. Vater
    • 2
  • U. Junker
    • 4
  • H.C. Wartenberg
    • 5
  1. 1.Abteilung für Anästhesie, Interdisziplinäre Intensivmedizin, Schmerztherapie, PalliativmedizinCURA - katholisches Krankenhaus im SiebengebirgeBad HonnefDeutschland
  2. 2.Klinik und Poliklinik für Anästhesiologie und Operative IntensivmedizinUniversitätskliniken BonnBonnDeutschland
  3. 3.Klinik für Psychiatrie und PsychotherapieUniversitätsklinikum des SaarlandesHomburg/SaarDeutschland
  4. 4.Abteilung Anästhesie, Spezielle Schmerztherapie und PalliativmedizinSana-Klinikum Remscheid, akademisches Lehrkrankenhaus der Ruhruniversität BochumRemscheidDeutschland
  5. 5.Afdeling AnesthesiologieAcademisch Medisch Centrum (AMC)AmsterdamNiederlande

Personalised recommendations